There's no cure as of now for multiple myeloma but treatments can help and help prevent the multiple myeloma from progressing.
Multiple Myeloma is a terminal cancer as there's no full on cure for it as of now.
However treatments can help prevent and slow the progression of the multiple myeloma cancer.
Myeloma is a relapsing-remitting cancer.
Multiple Myeloma is not always a death sentence since treatments are available to help prevent the spread of the disease.
Multiple Myeloma is a form of Leukemia of plasma cells.
Myeloma is a tumor of the bone marrow, and involves a specific subset of white blood cells that produce a distinctive protein.
Leukemia can arise in either of two main groups of white blood cell types -lymphocytes or myelocytes.
Multiple Myeloma is considered a rare disease and rare cancer.
The Multiple Myeloma is more common in males than it is in females.
Multiple myeloma is a rare type of deadly cancer that is slightly more common in males than females.
Over 32,000 individuals in the United States were diagnosed with multiple myeloma in 2019.
It is also believed that approximately 100,000 Americans currently have the multiple myeloma disease.
Multiple myeloma is considered a cancer of plasma cells, and non-Hodgkin lymphoma is a cancer of lymphocytes.
WM cells have features of both plasma cells and lymphocytes.
WM cells make large amounts of a certain type of antibody (immunoglobulin M, or IgM), which is known as a macroglobulin.
Multiple myeloma is classified by stage 1, 2, or 3. In multiple myeloma cases, stage 3 is the terminal stage.
This means it's the most advanced stage of this type of rare cancer.
Doctors use the international staging system to determine the stage of the cancer.
Multiple myeloma is a cancer that forms in a type of white blood cell called a plasma cell.
Healthy plasma cells help you fight infections by making antibodies that recognize and attack germs.
In multiple myeloma, cancerous plasma cells accumulate in the bone marrow and crowd out healthy blood cells.
Multiple myeloma is an uncommon cancer of the blood.
The median length of survival after diagnosis with multiple myeloma is 62 months for Stage I, 44 months for Stage II, and 29 months for Stage III.
Life expectancy depends on many factors, including the person's age, health, kidney function, and more.
Currently, there are also no obvious, strong risk factors for myeloma.
Although the mutations that cause myeloma are acquired and not inherited, family history is a known risk factor for multiple myeloma.
First-degree relatives of people with multiple myeloma have a 2 to 3 times higher risk of developing the disease.